ClinicalTrials.gg
RecruitingNCT06679101DREAMM-10Updated Apr 22, 2026

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

A Phase 3 interventional study of Belantamab mafodotin and Lenalidomide in Multiple Myeloma and Newly Diagnosed Multiple Myeloma, sponsored by GlaxoSmithKline. Recruiting at 181 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
520
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies testing belantamab mafodotin in Multiple Myeloma — 15 open to participants now, 35 under way, 8 of them phase 3. belantamab mafodotin · Multiple Myeloma.

Planned enrollment
Largest of 49
520 · median 50
Started
2024
with 3 others
Phase 3
9 of 49
2 open now
Primary completion
2031-04
later than 30 of 34 live
Registered
35th of 49
by date
Lead sponsor
24 of 49
GlaxoSmithKline

Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, this one has the largest planned enrollment, is one of 4 that started in 2024, is one of 9 in phase 3, reaches primary completion later than 30 of the 34 other live ones, and was the 35th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 49 studies testing belantamab mafodotin in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About belantamab mafodotin

belantamab mafodotin: first FDA approval 2020 (Blenrep), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing belantamab mafodotin in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.

03

Conditions studied

  • Multiple Myeloma
  • Newly Diagnosed Multiple Myeloma

Browse trials for

Keywords

  • Multiple myeloma
  • Belantamab mafodotin
  • Lenalidomide
  • Dexamethasone
  • Daratumumab
  • Transplant-ineligible
  • DREAMM-10
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is at least 18 or the legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the .
  2. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and in the protocol.
  3. NDMM with a requirement for treatment as documented per IMWG criteria.
  4. Must have at least 1 aspect of , as assessed by the central laboratory, defined as 1 of the following:

    1. Urine M-protein excretion ≥200 mg/24 hours (≥0.2 g/24 hours) And/or
    2. Serum M-protein concentration ≥0.5 g/dL (≥5.0 g/L) And/or
    3. Serum free light-chain (FLC) assay: involved FLC level ≥10 mg/dL (≥100 mg/L) and an abnormal serum FLC ratio (\<0.26 or >1.65).
  5. Newly diagnosed and not considered candidate for high-dose chemotherapy with stem cell transplant (ASCT) due to any of the following:

    1. Exclusion from treatment with ASCT due to country- or site-specific age restriction.
    2. Presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT.
  6. (ECOG) performance status of 0 to 2.
  7. Adequate organ system function as defined by the laboratory assessments.
  8. Male participants:

    • use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
    • Male participants are eligible to participate if they agree to the following during the Treatment Period and for at least 6 months after the last dose of study intervention to allow for clearance of any altered sperm:
    • Refrain from donating fresh unwashed semen

    PLUS either:

    • Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent.

    OR

    • Must agree to use contraception/barrier as detailed below
    • Agree to use a male condom, even if they have undergone a successful vasectomy, and female partner to use an additional highly effective contraceptive method with a failure rate of \<1% per year when having sexual intercourse with a woman of (WOCBP) who is not currently pregnant. Male participants should also use a condom when having sexual intercourse with pregnant females.
  9. Female participants

    • Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
    • A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies:
    • Is not a WOCBP OR
    • Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \<1% per year), preferably with low user dependency during the Treatment Period and for 4 months after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.
    • A WOCBP must have 2 negative highly sensitive serum pregnancy tests before starting treatment, the first may be performed within 14 days from C1D1, the second within 24 hours before the first dose of study intervention.
    • Should pregnancy occur in a female on treatment or the female partner of a male on treatment, treatment must be stopped, and it is advised to seek advice from a physician specialized or experienced in teratology.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of systemic amyloid light chain amyloidosis, Waldenstrom's disease, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma proliferative disorder, skin changes) or Primary Plasma Cell Leukemia (defined as circulating plasma cells >5%).
  2. Prior systemic therapy for multiple myeloma, or smoldering multiple myeloma.
  3. Signs of meningeal or central nervous system involvement with multiple myeloma.
  4. Major surgery within 2 weeks prior to the first dose of study drugs or has not recovered fully from surgery. Kyphoplasty is not considered major surgery.
  5. Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere with participant's safety, obtaining , or compliance with study procedures.
  6. Current active liver or biliary disease (except for Gilbert's syndrome or asymptomatic gallstones, or otherwise stable chronic liver disease as per the investigator's assessment).
  7. Participants with previous or concurrent other than multiple myeloma are excluded. Exceptions are any other malignancy that has been considered medically stable for at least 2 years, after discussion with the GSK Medical Monitor. The participant must not be receiving active therapy, other than hormonal therapy for this disease.
  8. Evidence of cardiovascular risk including any of the following:

    1. Evidence of current untreated arrhythmias, including clinically significant abnormalities including second-degree (Mobitz Type II) or third-degree atrioventricular block.
    2. Recent history (within 3 months of screening) of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty or stenting, or bypass grafting.
    3. Class III or IV heart failure as defined by the functional classification system.
  9. Known (HIV) infection, unless the participant can meet all of the following criteria:

    1. Established antiretroviral therapy for at least 4 weeks and HIV viral load \<400 copies/mL within Screening Period.
    2. CD4+ T-cell (CD4+) counts ≥350 cells/μL.
    3. No history of acquired immune deficiency syndrome-defining opportunistic infections within the last 12 months.
  10. Positive antibody test result or positive hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study intervention unless the participant can meet the following criteria:

    1. RNA test negative.
    2. Successful antiviral treatment (usually 8 weeks duration) is required, followed by a negative hepatitis C viral load RNA test after a of at least 4 weeks.
  11. Participants with will be excluded unless the defined criteria can be met.
  12. Current corneal epithelial disease except for mild punctate keratopathy.
  13. Intolerance or to antiviral prophylaxis.
  14. Unable to tolerate antithrombotic prophylaxis.
  15. Known immediate or delayed reaction or idiosyncratic reaction to drugs chemically related to belantamab mafodotin, or any of the components of the study intervention.
  16. Plasmapheresis within 7 days prior to the first dose of study intervention.
  17. Participants must not have received a live or within 30 days prior to first dose of belantamab mafodotin.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
520 participants (estimated)

Study arms

  • Experimental
    Arm A: Belantamab Mafodotin + Lenalidomide + Dexamethasone

    Belantamab mafodotin, lenalidomide, and dexamethasone will be administered. Treatment will continue in both arms until progressive disease (PD), death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.

    Drug: Belantamab mafodotin · Drug: Lenalidomide · Drug: Dexamethasone

  • Active comparator
    Arm B: Daratumumab + Lenalidomide + Dexamethasone

    Daratumumab, lenalidomide, and dexamethasone will be administered. Treatment will continue in both arms until PD, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.

    Drug: Lenalidomide · Drug: Dexamethasone · Drug: Daratumumab

Interventions

06

What researchers measure

Primary outcomes

  1. PFS

    Defined as the time from the date of randomization to the date of first documented PD per International Myeloma Working Group (IMWG) criteria by Independent Review Committee (IRC) or death from any cause in the absence of progression, whichever occurs first.

    Time frame: Up to approximately 7 years

  2. Number of Participants Achieving MRD Negative Status

    Defined as achieving MRD negativity at 10\^-5 sensitivity threshold (1 nucleated tumor cell in 100,000 normal cells) assessed by next-generation sequencing (NGS) at least once during the time of confirmed complete response (CR) or better response per IMWG criteria by IRC.

    Time frame: Up to approximately 7 years

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: Up to approximately 7 years

  2. PFS2

    Defined as the time from the date of randomization to the date of documented PD following the first subsequent anti-myeloma therapy or death from any cause, whichever is earlier.

    Time frame: Up to approximately 7 years

  3. Number of Participants Achieving CR or Better (CR+)

    Time frame: Up to approximately 7 years

  4. Number of Participants Achieving Very Good Partial Response (VGPR) or Better

    Time frame: Up to approximately 7 years

  5. Number of Participants Achieving Sustained MRD Negative Status

    Defined as achieving MRD negative status at 10\^-5 sensitivity threshold (1 nucleated tumor cell in 100,000 normal cells) assessed by NGS at least twice, a minimum of 1 year apart and with no MRD positive result in between, during the time of confirmed CR+ response per IMWG criteria by IRC.

    Time frame: Up to approximately 7 years

  6. Duration of Response (DoR)

    Time frame: Up to approximately 7 years

  7. Time to Second Next Line Therapy (TTST)

    Time frame: Up to approximately 7 years

  8. Number of Participants With Adverse Events (AEs)

    Time frame: Up to approximately 7 years

  9. Number of Participants With Ocular Findings on Ophthalmic Exam

    Time frame: Up to approximately 7 years

  10. Maximum Post-baseline Patient-Reported Outcomes Version of the Common Term Criteria for Adverse Events (PRO-CTCAE) Score

    Time frame: Up to approximately 7 years

  11. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30

    Time frame: Up to approximately 7 years

  12. Change From Baseline in EORTC QLQ-MY20

    Time frame: Up to approximately 7 years

  13. Plasma Concentrations of Belantamab Mafodotin

    Time frame: Up to approximately 7 years

  14. Plasma Concentrations of Cysteine Maleimidocaproyl Monomethyl Auristatin F (cys-mcMMAF)

    Time frame: Up to approximately 7 years

07

Study locations

181 of 181 sites recruiting
  • GSK Investigational Site
    Mobile, Alabama 36607, United States
    Recruiting
  • GSK Investigational Site
    Phoenix, Arizona 85054, United States
    Recruiting
  • GSK Investigational Site
    Beverly Hills, California 90211, United States
    Recruiting
  • GSK Investigational Site
    Pasadena, California 91105, United States
    Recruiting
  • GSK Investigational Site
    Aurora, Colorado 80012, United States
    Recruiting
  • GSK Investigational Site
    Washington D.C., District of Columbia 20007, United States
    Recruiting
  • GSK Investigational Site
    Englewood, Florida 34223, United States
    Recruiting
  • GSK Investigational Site
    Lady Lake, Florida 32159, United States
    Recruiting
  • GSK Investigational Site
    Pembroke Pines, Florida 33024, United States
    Recruiting
  • GSK Investigational Site
    Saint Augustine, Florida 32256, United States
    Recruiting
  • GSK Investigational Site
    Atlanta, Georgia 30322, United States
    Recruiting
  • GSK Investigational Site
    Portland, Maine 04074, United States
    Recruiting
  • GSK Investigational Site
    Worcester, Massachusetts 01655, United States
    Recruiting
  • GSK Investigational Site
    Ann Arbor, Michigan 48103, United States
    Recruiting
  • GSK Investigational Site
    Detroit, Michigan 48201, United States
    Recruiting
  • GSK Investigational Site
    Billings, Montana 59102, United States
    Recruiting
  • GSK Investigational Site
    Hackensack, New Jersey 07601, United States
    Recruiting
  • GSK Investigational Site
    New York, New York 10065, United States
    Recruiting
  • GSK Investigational Site
    Stony Brook, New York 11790, United States
    Recruiting
  • GSK Investigational Site
    Charlotte, North Carolina 28204, United States
    Recruiting
  • GSK Investigational Site
    Winston-Salem, North Carolina 27103, United States
    Recruiting
  • GSK Investigational Site
    Columbus, Ohio 43214, United States
    Recruiting
  • GSK Investigational Site
    Providence, Rhode Island 02903, United States
    Recruiting
  • GSK Investigational Site
    Austin, Texas 78705, United States
    Recruiting
  • GSK Investigational Site
    Austin, Texas 78712, United States
    Recruiting
  • GSK Investigational Site
    Kingwood, Texas 77339, United States
    Recruiting
  • GSK Investigational Site
    San Antonio, Texas 78240, United States
    Recruiting
  • GSK Investigational Site
    Tyler, Texas 75702, United States
    Recruiting
  • GSK Investigational Site
    Fairfax, Virginia 22031, United States
    Recruiting
  • GSK Investigational Site
    Puyallup, Washington 98373, United States
    Recruiting
  • GSK Investigational Site
    Capital Federal, C1426ANZ, Argentina
    Recruiting
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aire, 1414, Argentina
    Recruiting
  • GSK Investigational Site
    Córdoba, Argentina
    Recruiting
  • GSK Investigational Site
    Rosario, S2002, Argentina
    Recruiting
  • GSK Investigational Site
    Viedma, R8500ACE, Argentina
    Recruiting
  • GSK Investigational Site
    Gosford NSW, New South Wales 2250, Australia
    Recruiting
  • GSK Investigational Site
    Box Hill, Victoria 3128, Australia
    Recruiting
  • GSK Investigational Site
    Melbourne, Victoria 3004, Australia
    Recruiting
  • GSK Investigational Site
    Fitzroy, Australia
    Recruiting
  • GSK Investigational Site
    Herston, Australia
    Recruiting
  • GSK Investigational Site
    St Leonards, Australia
    Recruiting
  • GSK Investigational Site
    Bruges, 8000, Belgium
    Recruiting
  • GSK Investigational Site
    Brussels, 1200, Belgium
    Recruiting
  • GSK Investigational Site
    Ghent, 9000, Belgium
    Recruiting
  • GSK Investigational Site
    Hornu, 7301, Belgium
    Recruiting
  • GSK Investigational Site
    Roeselare, 8800, Belgium
    Recruiting
  • GSK Investigational Site
    Salvador, Estado de Bahia, Brazil
    Recruiting
  • GSK Investigational Site
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
    Recruiting
  • GSK Investigational Site
    Barretos, 14784-400, Brazil
    Recruiting
  • GSK Investigational Site
    Joinville, 89201-260, Brazil
    Recruiting
  • GSK Investigational Site
    Porto Alegre, Brazil
    Recruiting
  • GSK Investigational Site
    São Paulo, 01509-010, Brazil
    Recruiting
  • GSK Investigational Site
    São Paulo, 04537-080, Brazil
    Recruiting
  • GSK Investigational Site
    São Paulo, 05403-000, Brazil
    Recruiting
  • GSK Investigational Site
    São Paulo, Brazil
    Recruiting
  • GSK Investigational Site
    Teresina, 64049-200, Brazil
    Recruiting
  • GSK Investigational Site
    Vitória, 29043-260, Brazil
    Recruiting
  • GSK Investigational Site
    Saint John, New Brunswick E2L 4L2, Canada
    Recruiting
  • GSK Investigational Site
    Beijing, 100191, China
    Recruiting
  • GSK Investigational Site
    Chengdu, 610072, China
    Recruiting
  • GSK Investigational Site
    Chongqing, 400016, China
    Recruiting
  • GSK Investigational Site
    Guangzhou, 510060, China
    Recruiting
  • GSK Investigational Site
    Guangzhou, 510515, China
    Recruiting
  • GSK Investigational Site
    Hangzhou, 310003, China
    Recruiting
  • GSK Investigational Site
    Nanchang, 330000, China
    Recruiting
  • GSK Investigational Site
    Nanchang, China
    Recruiting
  • GSK Investigational Site
    Nanjing, 210008, China
    Recruiting
  • GSK Investigational Site
    Shanghai, 200032, China
    Recruiting
  • GSK Investigational Site
    Shanghia, 200080, China
    Recruiting
  • GSK Investigational Site
    Shenzhen, 430022, China
    Recruiting
  • GSK Investigational Site
    Shenzhen, 518039, China
    Recruiting
  • GSK Investigational Site
    Tianjin, 300020, China
    Recruiting
  • GSK Investigational Site
    Wenzhou, 325000, China
    Recruiting
  • GSK Investigational Site
    Xi'an, 710004, China
    Recruiting
  • GSK Investigational Site
    Ostrava, 708 52, Czechia
    Recruiting
  • GSK Investigational Site
    Prague, 100 34, Czechia
    Recruiting
  • GSK Investigational Site
    Bobigny, 93009, France
    Recruiting
  • GSK Investigational Site
    Nantes, 44202, France
    Recruiting
  • GSK Investigational Site
    Villejuif, 94805, France
    Recruiting
  • GSK Investigational Site
    Jena, Europe 7747, Germany
    Recruiting
  • GSK Investigational Site
    Lübeck, Schleswig-Holstein 23538, Germany
    Recruiting
  • GSK Investigational Site
    Chemnitz, 9116, Germany
    Recruiting
  • GSK Investigational Site
    Cologne, 50937, Germany
    Recruiting
  • GSK Investigational Site
    Dresden, 01307, Germany
    Recruiting
  • GSK Investigational Site
    Hamburg, 20246, Germany
    Recruiting
  • GSK Investigational Site
    Hanover, 30625, Germany
    Recruiting
  • GSK Investigational Site
    Mainz, 55131, Germany
    Recruiting
  • GSK Investigational Site
    Würzburg, 97080, Germany
    Recruiting
  • GSK Investigational Site
    Alexandroupoli, 68 100, Greece
    Recruiting
  • GSK Investigational Site
    Athens, 106 76, Greece
    Recruiting
  • GSK Investigational Site
    Athens, 115 28, Greece
    Recruiting
  • GSK Investigational Site
    Athens, Greece
    Recruiting
  • GSK Investigational Site
    Pátrai, 26504, Greece
    Recruiting
  • GSK Investigational Site
    Thessaloniki, 54007, Greece
    Recruiting
  • GSK Investigational Site
    Ahmedabad, 380009, India
    Recruiting
  • GSK Investigational Site
    Bangalore, 560054, India
    Recruiting
  • GSK Investigational Site
    Hyderabad, 500033, India
    Recruiting
  • GSK Investigational Site
    Kolkata, 700014, India
    Recruiting
  • GSK Investigational Site
    Kolkata, 700156, India
    Recruiting
  • GSK Investigational Site
    Pune, 411001, India
    Recruiting

Showing the first 100 of 181 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Apr 2031, 76 months after the start.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's planned 76 months is above that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2024
First posted
Nov 7, 2024
StartActual
Dec 16, 2024
Primary completionEst.
Apr 28, 2031
CompletionEst.
Apr 28, 2031
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06679101
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 7, 2024
Start date
Dec 16, 2024
Primary completion
Apr 28, 2031 (estimated)
Completion
Apr 28, 2031 (estimated)
Last update
Apr 22, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belantamab mafodotin

Start the discussion